All In Biotech

Free tool

FAERS Monitor: Aminosyn Ii 10% In Plastic Container

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020015 or its brand name (Aminosyn Ii 10% In Plastic Container, Amino Acids). Reports on generic versions are filed under their own applications.

Reports

4

Serious

2

50% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • arthralgia1
  • furuncle1
  • pain in extremity1
  • product colour issue1
  • product dispensing error1
  • product odour abnormal1
  • product preparation error1
  • product quality issue1
  • product supply issue1
  • rheumatoid arthritis1
  • uterine disorder1

Reports by year received

View as table
YearReports
20141
20151
20182

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
uterine disorder12258.1413.4563
product colour issue11024.6187.6255
product supply issue1736.7134.9183
furuncle1663.8121.6165
product odour abnormal1502.192.0125
product preparation error1255.946.963
product dispensing error1241.544.259
rheumatoid arthritis146.38.511
product quality issue138.77.19
pain in extremity117.83.34
arthralgia112.62.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.